According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma? READ MORE

Conferences

Researchers have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy pembrolizumab.

READ MORE

J Code Updates

News

A recent study found that multiple factors including insurance status, ethnicity, and individual providing the diagnosis are associated with delays in treatment for patients with melanoma.

READ MORE

An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma.

READ MORE

Recently published long-term survival data shows the benefits of combining two conventional therapies to treat patients with advanced melanoma.

READ MORE

Bristol-Myers Squibb’s immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.

READ MORE

Research in Review

Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety.

READ MORE

Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days.

READ MORE

Central nervous system imaging is needed during programmed death 1 inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases.

READ MORE

Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress.

READ MORE

Resources

The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.

READ MORE